



18th INDUSTRY/ACADEMIA NEXT GENERATION PRECISION ONCOLOGY SYMPOSIUM

THURSDAY SEPTEMBER 15, 2022 | 8AM - 6PM | THE ALEXANDRIA AT TORREY PINES

8:00-9:00 Registration and Continental Breakfast

9:00-9:15 **Opening Remarks**

Ida Deichaite, PhD, Director, Industry Relations, Moores Cancer Center, Assistant Adjunct Professor, Radiation Medicine & Applied Sciences, UC San Diego

Steven Garfin, MD, Interim Vice Chancellor, Health Sciences, Interim Dean, School of Medicine, UC San Diego

9:15-10:30 **Session I**

Moderator: Scott Lippman, MD, Director, Moores Cancer Center, Senior Associate Dean & AVC Cancer Research and Care, Professor of Medicine, UC San Diego

9:15 **Tomivosertib: Enhancing T cell function through translational regulation of gene expression**
Steve Worland, PhD, President and Chief Executive Officer, eFFECTOR Therapeutics

9:30 **Targeting macrophage Syk to promote anti-tumor immunity**
Shweta Joshi, PhD, Assistant Professor, Department of Pediatrics, Moores Cancer Center, UC San Diego

9:45 **First-in-human study of XmAb808, a CD28 x B7H3 bispecific antibody, in combination with pembrolizumab in advanced solid tumors**
Ben Thompson, MD, PhD, Medical Director, Clinical Development, Xencor

10:00 **Impact of aberrant splicing alteration in HNSCC on prognosis and response to immune checkpoint inhibition**
Theresa Guo, MD, Assistant Professor, Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, Moores Cancer Center, UC San Diego

10:15 Q&A and Discussion

10:30-12:15 **Session II**

Moderator: Thomas Kipps, MD, PhD, Distinguished Professor of Medicine, Moores Cancer Center, Director, Center for Novel Therapeutics, UC San Diego

10:30 **Hijacking stromal signals to turn immune-cold tumors into immune-hot**
Fotis Asimakopoulos, MB BChir, PhD, Associate Professor, Division of Blood and Marrow Transplantation, Department of Medicine, Moores Cancer Center, UC San Diego

10:45 **Leveraging T cell adaptations to tissue residency to enhance anti-tumor immunity**
Ananda Goldrath, PhD, Tata Chancellor's Professor, Division of Biological Sciences, Molecular Biology, UC San Diego

11:00 Q&A and Discussion

11:15-11:30 Break

11:30 **Keynote Presentation**

CAR T Cells – From Spark to Fire

Kristen Hege, MD, Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy, Bristol Myers Squibb

12:00-12:15 **Duane Roth Award Presentation**

12:15-1:30 Lunch

(continued on back)



18th INDUSTRY/ACADEMIA NEXT GENERATION PRECISION ONCOLOGY SYMPOSIUM

THURSDAY SEPTEMBER 15, 2022 | 8AM - 6PM | THE ALEXANDRIA AT TORREY PINES

1:30-3:15 *Session III*

Moderator: Ezra Cohen, MD, FRCPC, FASCO, Chief, Division of Hematology/Oncology, Department of Medicine, Moores Cancer Center, Co-Director, Hanna and Mark Gliberman Head and Neck Cancer Center, UC San Diego

Moderator: J. Silvio Gutkind, PhD, Distinguished Professor and Chief, Department of Pharmacology, Associate Director of Basic Science, Moores Cancer Center, UC San Diego

1:30 *Development of INBRX-109, a best in class tetravalent DR5 agonist, for the treatment of cancer*
Brendan Eckelman, PhD, Chief Scientific Officer, EVP Corporate Strategy, INHIBRx

1:45 *Targeting cellular mechanotransduction to inhibit tumor invasion and metastasis*
Jing Yang, PhD, Professor of Pharmacology and Pediatrics, Moores Cancer Center, UC San Diego

2:00 *Development of a Subcutaneous Checkpoint Inhibitor in Sarcoma—a Disease Whose Most Effective Drug was Approved 30 Years Ago*
Charles Theuer, MD, PhD, President, Chief Executive Officer, TRACON Pharmaceuticals

2:15 *The role of the sentinel node in response to immunoradiotherapy*
Joseph Califano, MD, Physician in Chief, Moores Cancer Center, Director, Hanna and Mark Gliberman Head and Neck Cancer Center, Department of Otolaryngology-Head and Neck Surgery, UC San Diego

2:30 *MRTX1719: a selective PRMT5/MTA complex inhibitor being developed as a synthetic lethal precision medicine for MTAP/CDKN2A deleted cancers*
Peter Olson, PhD, Executive Director of Research, Mirati Therapeutics

2:45 *DRP-104 (Sirpiglenastat), A Broad Glutamine Antagonist, Induces Anti-Tumor Activity by Directly Inhibiting Glutamine Metabolism and Stimulating the Innate & Adaptive Immune Systems*
Robert Wild, PhD, Chief Scientific Officer, Dracen Pharmaceuticals

3:00 *Q&A and Discussion*

3:15-3:30 Break

3:30-5:15 *Session IV*

Moderator: Catriona Jamieson, MD, PhD, Professor of Medicine, Deputy Director, Moores Cancer Center, Chief, Division of Regenerative Medicine, Director, Sanford Stem Cell Clinical Center, UC San Diego

3:30 *Activation of Latent Oncogenic Viruses as a Form of Targeted Cancer Therapy*
Ayman El-Guindy, PhD, Chief Scientific Officer, Viracta Therapeutics

3:45 *Engineering Human iPSCs to Produce Immune Cells with Improved Anti-Tumor Activity*
Dan Kaufman, MD, PhD, Professor of Medicine, Division of Regenerative Medicine, Director of Cell Therapy, UC San Diego

4:00 *Understanding Human Genetic Variation with Precision Genome Editing Tools*
Alexis Komor, PhD, Assistant Professor, Department of Chemistry and Biochemistry, UC San Diego

4:15 *Q&A and Discussion*

4:30 **Keynote Presentation**

Next Generation CAR T Cells for cancer and beyond

Carl June, MD, Richard W. Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine, Director, Center for Cellular Immunotherapies, Perelman School of Medicine, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania

5:15 Networking Reception